Search research articles
Contact Us
Filters
Showing results (311-320 of 578) with videos related to
Page
of 58
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2015
Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study
Elisabeth Maritschnegg, Yuxuan Wang, Nina Pecha, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2016
Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64]
Sandrina Lambrechts, Dominiek Smeets, Matthieu Moisse, et al.
Oncotarget
|
January 2, 2018
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium
Eva Obermayr, Natalia Bednarz-Knoll, Beatrice Orsetti, et al.
Gynecologic Oncology
|
November 10, 2006
A new prognostic model for FIGO stage 1 epithelial ovarian cancer
Andreas Obermair, Arlan Fuller, Elisa Lopez-Varela, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2014
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Sven Mahner, Werner Meier, Andreas du Bois, et al.
Stem Cell Reports
|
April 4, 2020
Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models
Nina Maenhoudt, Charlotte Defraye, Matteo Boretto, et al.
JCO Precision Oncology
|
June 26, 2023
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
Yann Christinat, Liza Ho, Sophie Clément, et al.
Gynecologic Oncology
|
January 21, 2020
Second-line lenvatinib in patients with recurrent endometrial cancer
Ignace Vergote, Matthew A Powell, Michael G Teneriello, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
Targeted Oncology
|
May 26, 2015
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
Evelyn Despierre, Ignace Vergote, Ryan Anderson, et al.
Page
of 58
Search research articles
Search
Showing results (311-320 of 578) with videos related to
Sort By:
Page
of 58
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 11, 2015
Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study
Elisabeth Maritschnegg, Yuxuan Wang, Nina Pecha, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 24, 2016
Corrigendum to "Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer" [Eur J Cancer 53 (2016) 51-64]
Sandrina Lambrechts, Dominiek Smeets, Matthieu Moisse, et al.
Oncotarget
|
January 2, 2018
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium
Eva Obermayr, Natalia Bednarz-Knoll, Beatrice Orsetti, et al.
Gynecologic Oncology
|
November 10, 2006
A new prognostic model for FIGO stage 1 epithelial ovarian cancer
Andreas Obermair, Arlan Fuller, Elisa Lopez-Varela, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 24, 2014
Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trial
Sven Mahner, Werner Meier, Andreas du Bois, et al.
Stem Cell Reports
|
April 4, 2020
Developing Organoids from Ovarian Cancer as Experimental and Preclinical Models
Nina Maenhoudt, Charlotte Defraye, Matteo Boretto, et al.
JCO Precision Oncology
|
June 26, 2023
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
Yann Christinat, Liza Ho, Sophie Clément, et al.
Gynecologic Oncology
|
January 21, 2020
Second-line lenvatinib in patients with recurrent endometrial cancer
Ignace Vergote, Matthew A Powell, Michael G Teneriello, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 29, 2011
Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG)
Gordon John Sampson Rustin, Ignace Vergote, Elizabeth Eisenhauer, et al.
Targeted Oncology
|
May 26, 2015
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy
Evelyn Despierre, Ignace Vergote, Ryan Anderson, et al.
Page
of 58